| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Akebia Therapeutics (NASDAQ:AKBA) through any online brokerage.
Other companies in Akebia Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Akebia Therapeutics has a consensus price target of $4.71.
The stock price for Akebia Therapeutics (NASDAQ: AKBA) is $0.807542 last updated October 9, 2026 at 5:49 PM EDT.
There are no upcoming dividends for Akebia Therapeutics.
Akebia Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Akebia Therapeutics.
Akebia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
